[go: up one dir, main page]

SUN et al., 1956 - Google Patents

Optimal effective dose of anticholinergic drug in peptic ulcer therapy

SUN et al., 1956

Document ID
7044383404777896555
Author
SUN D
SHAY H
Publication year
Publication venue
AMA Archives of Internal Medicine

External Links

Snippet

In our previous study 1 on the effect of different doses of an anticholinergic drug in the same patient, we found that suppression of gastric acidity to pH 4.5 or higher did not occur at any dose without accompanying dryness of the mouth but that the dose producing dryness of the …
Continue reading at jamanetwork.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00—Drug, bio-affecting and body treating compositions
    • Y10S514/899—Menstrual disorder
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00—Drug, bio-affecting and body treating compositions
    • Y10S514/857—Dermatitis
    • Y10S514/861—Eczema

Similar Documents

Publication Publication Date Title
SUN et al. Optimal effective dose of anticholinergic drug in peptic ulcer therapy
Thorn et al. Addison's disease: evaluation of synthetic desoxycorticosterone acetate therapy in 158 patients
Hart et al. Indomethacin: a new non-steroid anti-inflammatory agent
Shayne et al. Thyrotoxic periodic paralysis terminated with intravenous propranolol
Copeman et al. Cortisone and other steroids in rheumatoid arthritis
Nugent et al. Glucocorticoid toxicity: single contrasted with divided daily doses of prednisolone
Thompson et al. Long term uricosuric therapy in gout
Grimson et al. SUCCESSFUL TREATMENT OF HYPERHIDROSIS USING BANTHINE®
LAYZER et al. Periodic paralysis caused by abuse of thyroid hormone
Cleghorn et al. The treatment of Addison's disease by a synthetic adrenal cortical hormone (desoxycorticosterone acetate)
HOWARD et al. Effects of pituitary adrenocorticotropic hormone (ACTH) on the hypersensitive state
Paschkis et al. Thiourea and thiouracil in treatment of thyrotoxicosis
Minto et al. “Temposil” a new drug in the treatment of alcoholism
Perera et al. Clinical and metabolic study of 17-hydroxycorticosterone (Kendall Compound F); comparison with cortisone.
Kirsner et al. Pamine bromide: Gastric antisecretory effects and therapeutic usefulness in peptic ulcer and other gastrointestinal disorders
Greene et al. Effect of D-thyroxine on serum cholesterol
Wood et al. Urinary excretion of prednisolone after intrarectal therapy in ulcerative colitis
Reveno Thiouracil in angina pectoris
Joffe et al. Effect of oral hypoglycaemic agents on glucose tolerance in pancreatic diabetes
Bachrach Studies on a new anticholinergic drug, Marplan
Lam et al. Reducing meal-stimulated acid secretion versus reducing nocturnal acid secretion for healing of duodenal ulcer
Molthan et al. Clinical use of potassium para-aminosalicylate (KPAS)
Cobb Stiff man syndrome: is the lesion at spinal cord or brain stem level
Looney et al. The effect of dinitrophenol on the metabolism as seen in schizophrenic patients
WILLIAMS et al. THE ANTITHYROID ACTION OF 5-IODOTHIOURAGIL, 6-METHYL-5-IODOTHIOURACIL, THIOCYTOSINE AND (Ca) 4-n-PROPYL-6-OXYPYRIMIDYL-2-MERCAPTOACETIC ACID